Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine for First-Line Treatment of Patients With Metastatic Pancreatic Cancer From the US Societal Perspective

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.03.1607
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV


Related search